ホーム計算ツール

代理店ログイン

検索結果

Search Results for " MGCD265 analog "

ターゲット

Apoptosis VEGFR c-Met/HGFR

3

阻害剤

カタログ番号	製品名	別名	ターゲット
T6351	MGCD-265 analog	MGCD-265,Glesatinib	Apoptosis , VEGFR , c-Met/HGFR
	MGCD-265 analog (Glesatinib) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively.		Apoptosis , VEGFR , c-Met/HGFR
T15384	Glesatinib	MGCD265	c-Met/HGFR
	Glesatinib is an orally active and potent dual inhibitor of MET/SMO. Glesatinib is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC.		c-Met/HGFR
T15383	Glesatinib hydrochloride	MGCD265 hydrochloride	c-Met/HGFR
	Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO. Glesatinib hydrochloride is also a tyrosine kinase inhibitor. It antagonizes P-glycoprotein mediated multidrug resistance (MDR) in NSCLC.		c-Met/HGFR

Compounds

MGCD-265 analog

Synonym: MGCD-265,Glesatinib

Target: Apoptosis, VEGFR, c-Met/HGFR

Synonym: MGCD265

Target: c-Met/HGFR

Glesatinib hydrochloride

Synonym: MGCD265 hydrochloride

Target: c-Met/HGFR

本ウェブサイトに掲載されている製品は全て研究用試薬です。研究目的以外の用途にはご使用できません。

Copyright © 2015-2023 TargetMol Chemicals Inc. All rights reserved.